Diamyd Medical Aktiebolag has announced a significant financial move, entering into equity financing agreements with U.S. Sector specialist investors to secure up to USD 125 million. The company will issue 17,226,500 new Class B shares at a subscription price of SEK 13.54 per share, resulting in approximately SEK 233 million before transaction costs. This financial strategy, which includes the issuance of 46,649,362 warrants, aims to bolster the company’s cash position and support its ongoing clinical efforts.
The financing comes at a crucial time as the company has also confirmed the full enrollment of its pivotal Phase 3 clinical trial, DIAGNODE-3, which evaluates the efficacy of retogatein (rhGAD65) in individuals with type 1 diabetes. This trial involves 321 patients across 57 clinical sites in Europe and the U.S., with interim analysis results expected to be released on March 27, 2026.
Ulf Hannelius, President and CEO of Diamyd Medical, expressed optimism about the new investments, stating, “We are pleased to welcome leading U.S. Sector specialist investors at this pivotal stage. Their participation brings deep sector expertise and strong alignment with the U.S. Market, which will be central to our future development and commercialization strategy.” This round of financing is anticipated to extend the company’s operational runway and assist in pre-commercial preparations for retogatein, as well as the continued development of its precision medicine platform.
Financial Details and Implications
The Board of Directors has approved the issuance of new shares and warrants as part of a directed financing initiative. The Class B shares will increase the total number from 137,758,000 to 154,984,500 shares, with a corresponding increase in votes. The company has structured this financing to include participation from notable U.S. Investors such as Perceptive Advisors, RA Capital Management, and others, creating a broader shareholder base and enhancing liquidity.
Use of Proceeds
The proceeds from the share issue will primarily fund the completion of the DIAGNODE-3 trial. If all warrants are exercised, the company could receive additional funds of approximately SEK 933 million, which would be allocated for pre-commercial activities, life cycle management opportunities, and further pipeline development. The warrants may be exercised until at least September 30, 2027, providing a flexible capital structure for the company.
Future Outlook
The financing strategy and successful trial enrollment mark a critical juncture for Diamyd Medical, as it aims to position retogatein as a leading treatment option in the type 1 diabetes market. The upcoming interim analysis results will be a key indicator of the drug’s efficacy and could impact the company’s pathway toward potential accelerated approval in the U.S.
As the company navigates through this pivotal phase, stakeholders are encouraged to watch for the interim analysis results and subsequent developments in the upcoming extraordinary general meeting scheduled for April 8, 2026, which will address additional warrant issuances.
For more information and updates, stakeholders and interested parties are encouraged to follow the developments from Diamyd Medical as they embark on this significant journey in diabetes treatment.
